<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701168</url>
  </required_header>
  <id_info>
    <org_study_id>LJCC 07-04</org_study_id>
    <nct_id>NCT00701168</nct_id>
  </id_info>
  <brief_title>Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer</brief_title>
  <official_title>A Humanitarian Device Exemption Use Protocol of Therasphere® for Treatment of Unresectable Hepatocellular and Metastatic Liver Tumors - HDE #980006</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leo W. Jenkins Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leo W. Jenkins Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to provide supervised and limited access to Therasphere®
      treatment for patients with primary liver cancer and chemotherapy refractory liver metastasis
      who cannot be treated by surgical removal of the affected part of the liver. Patient response
      to treatment and any side effects of Therasphere® treatment will be examined.
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Carcinoma, Hepatocellular</condition>
  <condition>Neoplasm Metastasis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>yttrium Y 90 microspheres (Therasphere®)</intervention_name>
    <description>This is a local therapy for unresectable liver tumors with limited treatment options. It may be repeated under special circumstances.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of primary or metastatic intrahepatic carcinoma

          -  The cancer must be unresectable with limited established treatment options

          -  ECOG Performance Status Score 0-2

          -  Age 19 years or older

          -  Able to comprehend and provide written informed consent

        Exclusion Criteria:

          -  Any pre-treatment laboratory findings within 15 days of treatment demonstrating:

          -  Absolute granulocyte count ≤ 1,500/ul

          -  Platelet count ≤ 75,000/ul

          -  Serum creatinine &gt; 2.0 mg/dl

          -  Serum bilirubin ≥ 2.0 mg/dl

          -  Any of the following contraindications to angiography and selective visceral
             catheterization:

          -  History of severe allergy or intolerance to any contrast media, narcotics, sedatives,
             or atropine

          -  Bleeding, diathesis, not correctable by usual forms of therapy

          -  Severe peripheral vascular disease that would preclude catheterization

          -  Substantial venous shunt away from the liver

          -  Evidence of potential delivery of greater than 11 mCi (20 Gy absorbed dose) of
             radiation to the lungs on either 1) first Therasphere® administration; or 2)
             cumulative delivery of radiation to the lungs over multiple treatments

          -  Evidence of any detectable Tc-99 MAA flow to the stomach or duodenum, application of
             established angiographic techniques to stop such flow

          -  Significant extrahepatic disease representing an imminent life- threatening situation
             outcome

          -  Severe liver dysfunction or pulmonary insufficiency

          -  Active uncontrolled infection

          -  Significant underlying medical or psychiatric illness

          -  Pregnant women may not participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Suzanne Russo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>East Carolina University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leo W Jenkins Cancer Center at East Carolina University School of Medicine</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Houle S, Yip TK, Shepherd FA, Rotstein LE, Sniderman KW, Theis E, Cawthorn RH, Richmond-Cox K. Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres. Radiology. 1989 Sep;172(3):857-60.</citation>
    <PMID>2549567</PMID>
  </reference>
  <reference>
    <citation>Andrews JC, Walker-Andrews SC, Juni JE, Warber S, Ensminger WD. Modulation of liver tumor blood flow with hepatic arterial epinephrine: a SPECT study. Radiology. 1989 Dec;173(3):645-7.</citation>
    <PMID>2813766</PMID>
  </reference>
  <reference>
    <citation>Wollner I, Knutsen C, Smith P, Prieskorn D, Chrisp C, Andrews J, Juni J, Warber S, Klevering J, Crudup J, et al. Effects of hepatic arterial yttrium 90 glass microspheres in dogs. Cancer. 1988 Apr 1;61(7):1336-44.</citation>
    <PMID>3345490</PMID>
  </reference>
  <reference>
    <citation>Ziessman HA, Thrall JH, Gyves JW, Ensminger WD, Niederhuber JE, Tuscan M, Walker S. Quantitative hepatic arterial perfusion scintigraphy and starch microspheres in cancer chemotherapy. J Nucl Med. 1983 Oct;24(10):871-5.</citation>
    <PMID>6225839</PMID>
  </reference>
  <reference>
    <citation>Nakamura H, Tanaka M, Oi H. Hepatic embolization from the common hepatic artery using balloon occlusion technique. AJR Am J Roentgenol. 1985 Jul;145(1):115-6.</citation>
    <PMID>3873830</PMID>
  </reference>
  <reference>
    <citation>Wellwood JM, Cady B, Oberfield RA. Treatment of primary liver cancer: response to regional chemotherapy. Clin Oncol. 1979 Mar;5(1):25-31.</citation>
    <PMID>217565</PMID>
  </reference>
  <reference>
    <citation>Reed ML, Vaitkevicius VK, Al-Sarraf M, Vaughn CB, Singhakowinta A, Sexon-Porte M, Izbicki R, Baker L, Straatsma GW. The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: ten-year results of 124 patients in a prospective protocol. Cancer. 1981 Jan 15;47(2):402-9.</citation>
    <PMID>6257376</PMID>
  </reference>
  <reference>
    <citation>Dusheiko GM, Hobbs KE, Dick R, Burroughs AK. Treatment of small hepatocellular carcinomas. Lancet. 1992 Aug 1;340(8814):285-8. Review.</citation>
    <PMID>1353202</PMID>
  </reference>
  <reference>
    <citation>Kirk S, Blumgart R, Craig B, Rosen A, Terblanche J, Spence RA. Irresectable hepatoma treated by intrahepatic iodized oil doxorubicin hydrochloride: initial results. Surgery. 1991 Jun;109(6):694-7.</citation>
    <PMID>1645890</PMID>
  </reference>
  <reference>
    <citation>Ravoet C, Bleiberg H, Gerard B. Non-surgical treatment of hepatocarcinoma. J Surg Oncol Suppl. 1993;3:104-11. Review.</citation>
    <PMID>8389154</PMID>
  </reference>
  <reference>
    <citation>Audisio RA, Doci R, Mazzaferro V, Bellegotti L, Tommasini M, Montalto F, Marchianò A, Piva A, DeFazio C, Damascelli B, et al. Hepatic arterial embolization with microencapsulated mitomycin C for unresectable hepatocellular carcinoma in cirrhosis. Cancer. 1990 Jul 15;66(2):228-36.</citation>
    <PMID>2164435</PMID>
  </reference>
  <reference>
    <citation>Ichihara T, Sakamoto K, Mori K, Akagi M. Transcatheter arterial chemoembolization therapy for hepatocellular carcinoma using polylactic acid microspheres containing aclarubicin hydrochloride. Cancer Res. 1989 Aug 1;49(15):4357-62.</citation>
    <PMID>2472878</PMID>
  </reference>
  <reference>
    <citation>Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer. 1996 Jun 1;77(11):2217-22.</citation>
    <PMID>8635087</PMID>
  </reference>
  <reference>
    <citation>Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. NIH conference. Hepatocellular carcinoma. Ann Intern Med. 1988 Mar;108(3):390-401. Review.</citation>
    <PMID>2449110</PMID>
  </reference>
  <reference>
    <citation>Kassianides C, Kew MC. The clinical manifestations and natural history of hepatocellular carcinoma. Gastroenterol Clin North Am. 1987 Dec;16(4):553-62. Review.</citation>
    <PMID>2831150</PMID>
  </reference>
  <reference>
    <citation>Gores GJ, Steers JL. Progress in orthotopic liver transplantation for hepatocellular carcinoma. Gastroenterology. 1993 Jan;104(1):317-20.</citation>
    <PMID>8380396</PMID>
  </reference>
  <reference>
    <citation>Marcos-Alvarez A, Jenkins RL, Washburn WK, Lewis WD, Stuart KE, Gordon FD, Kane RA, Clouse ME. Multimodality treatment of hepatocellular carcinoma in a hepatobiliary specialty center. Arch Surg. 1996 Mar;131(3):292-8.</citation>
    <PMID>8611095</PMID>
  </reference>
  <reference>
    <citation>Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996 Mar 14;334(11):693-9.</citation>
    <PMID>8594428</PMID>
  </reference>
  <reference>
    <citation>Selby R, Kadry Z, Carr B, Tzakis A, Madariaga JR, Iwatsuki S. Liver transplantation for hepatocellular carcinoma. World J Surg. 1995 Jan-Feb;19(1):53-8.</citation>
    <PMID>7740811</PMID>
  </reference>
  <reference>
    <citation>Venook AP. Treatment of hepatocellular carcinoma: too many options? J Clin Oncol. 1994 Jun;12(6):1323-34. Review.</citation>
    <PMID>8201395</PMID>
  </reference>
  <reference>
    <citation>Ramming KP. The effectiveness of hepatic artery infusion in treatment of primary hepatobiliary tumors. Semin Oncol. 1983 Jun;10(2):199-205.</citation>
    <PMID>6306834</PMID>
  </reference>
  <reference>
    <citation>Nerenstone S, Friedman M. Medical treatment of hepatocellular carcinoma. Gastroenterol Clin North Am. 1987 Dec;16(4):603-12. Review.</citation>
    <PMID>2831153</PMID>
  </reference>
  <reference>
    <citation>Solomon B, Soulen MC, Baum RA, Haskal ZJ, Shlansky-Goldberg RD, Cope C. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population. J Vasc Interv Radiol. 1999 Jun;10(6):793-8.</citation>
    <PMID>10392950</PMID>
  </reference>
  <reference>
    <citation>BREEDIS C, YOUNG G. The blood supply of neoplasms in the liver. Am J Pathol. 1954 Sep-Oct;30(5):969-77.</citation>
    <PMID>13197542</PMID>
  </reference>
  <reference>
    <citation>SCHENK WG Jr, McDONALD JC, McDONALD K, DRAPANAS T. Direct measurement of hepatic blood flow in surgical patients: with related observations on hepatic flow dynamics in experimental animals. Ann Surg. 1962 Sep;156:463-71.</citation>
    <PMID>14498225</PMID>
  </reference>
  <reference>
    <citation>Sasaki Y, Imaoka S, Kasugai H, Fujita M, Kawamoto S, Ishiguro S, Kojima J, Ishikawa O, Ohigashi H, Furukawa H, et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer. 1987 Sep 15;60(6):1194-203.</citation>
    <PMID>2441837</PMID>
  </reference>
  <reference>
    <citation>Yamada R, Kishi K, Sato M, Sonomura T, Nishida N, Tanaka K, Shioyama Y, Terada M, Kimura M. Transcatheter arterial chemoembolization (TACE) in the treatment of unresectable liver cancer. World J Surg. 1995 Nov-Dec;19(6):795-800.</citation>
    <PMID>8553668</PMID>
  </reference>
  <reference>
    <citation>Madden MV, Krige JE, Bailey S, Beningfield SJ, Geddes C, Werner ID, Terblanche J. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut. 1993 Nov;34(11):1598-600.</citation>
    <PMID>8244149</PMID>
  </reference>
  <reference>
    <citation>Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med. 1995 May 11;332(19):1256-61.</citation>
    <PMID>7708069</PMID>
  </reference>
  <reference>
    <citation>Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, Lenoir C, Attali P, Etienne JP. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol. 1990 Sep;11(2):181-4.</citation>
    <PMID>2174933</PMID>
  </reference>
  <reference>
    <citation>Bruix J, Llovet JM, Castells A, Montañá X, Brú C, Ayuso MC, Vilana R, Rodés J. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology. 1998 Jun;27(6):1578-83.</citation>
    <PMID>9620330</PMID>
  </reference>
  <reference>
    <citation>Uchida M, Kohno H, Kubota H, Hayashi T, Yamanoi A, Kimoto T, Ono T, Nagasue N. Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma. World J Surg. 1996 Mar-Apr;20(3):326-31.</citation>
    <PMID>8661839</PMID>
  </reference>
  <reference>
    <citation>Stuart K, Stokes K, Jenkins R, Trey C, Clouse M. Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization. Cancer. 1993 Dec 1;72(11):3202-9.</citation>
    <PMID>7694787</PMID>
  </reference>
  <reference>
    <citation>Berger DH, Carrasco CH, Hohn DC, Curley SA. Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: post-treatment management and complications. J Surg Oncol. 1995 Oct;60(2):116-21.</citation>
    <PMID>7564377</PMID>
  </reference>
  <reference>
    <citation>Vetter D, Wenger JJ, Bergier JM, Doffoel M, Bockel R. Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a Western comparative study in 60 patients. Hepatology. 1991 Mar;13(3):427-33.</citation>
    <PMID>1847892</PMID>
  </reference>
  <reference>
    <citation>Perry LJ, Stuart K, Stokes KR, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery. 1994 Dec;116(6):1111-6; discussion 1116-7.</citation>
    <PMID>7985095</PMID>
  </reference>
  <reference>
    <citation>Ehrhardt GJ, Day DE. Therapeutic use of 90Y microspheres. Int J Rad Appl Instrum B. 1987;14(3):233-42.</citation>
    <PMID>3667306</PMID>
  </reference>
  <reference>
    <citation>Mantravadi RV, Spigos DG, Tan WS, Felix EL. Intraarterial yttrium 90 in the treatment of hepatic malignancy. Radiology. 1982 Mar;142(3):783-6.</citation>
    <PMID>7063703</PMID>
  </reference>
  <reference>
    <citation>Herba MJ, Illescas FF, Thirlwell MP, Boos GJ, Rosenthall L, Atri M, Bret PM. Hepatic malignancies: improved treatment with intraarterial Y-90. Radiology. 1988 Nov;169(2):311-4.</citation>
    <PMID>3174978</PMID>
  </reference>
  <reference>
    <citation>Blanchard RJ, Morrow IM, Sutherland JB. Treatment of liver tumors with yttrium-90 microspheres alone. Can Assoc Radiol J. 1989 Aug;40(4):206-10.</citation>
    <PMID>2766018</PMID>
  </reference>
  <reference>
    <citation>Andrews JC, Walker SC, Ackermann RJ, Cotton LA, Ensminger WD, Shapiro B. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med. 1994 Oct;35(10):1637-44.</citation>
    <PMID>7931662</PMID>
  </reference>
  <reference>
    <citation>BLANCHARD RJ, GROTENHUIS I, LAFAVE JW, PERRY JF Jr. BLOOD SUPPLY TO HEPATIC V2 CARCINOMA IMPLANTS AS MEASURED BY RADIOACTIVE MICROSPHERES. Proc Soc Exp Biol Med. 1965 Feb;118:465-8.</citation>
    <PMID>14268654</PMID>
  </reference>
  <reference>
    <citation>Stribley KV, Gray BN, Chmiel RL, Heggie JC, Bennett RC. Internal radiotherapy for hepatic metastases II: The blood supply to hepatic metastases. J Surg Res. 1983 Jan;34(1):25-32.</citation>
    <PMID>6681644</PMID>
  </reference>
  <reference>
    <citation>Gyves JW, Ziessman HA, Ensminger WD, Thrall JH, Niederhuber JE, Keyes JW Jr, Walker S. Definition of hepatic tumor microcirculation by single photon emission computerized tomography (SPECT). J Nucl Med. 1984 Sep;25(9):972-7.</citation>
    <PMID>6088735</PMID>
  </reference>
  <reference>
    <citation>Chamberlain MN, Gray BN, Heggie JC, Chmiel RL, Bennett RC. Hepatic metastases--a physiological approach to treatment. Br J Surg. 1983 Oct;70(10):596-8.</citation>
    <PMID>6626920</PMID>
  </reference>
  <reference>
    <citation>Meade VM, Burton MA, Gray BN, Self GW. Distribution of different sized microspheres in experimental hepatic tumours. Eur J Cancer Clin Oncol. 1987 Jan;23(1):37-41.</citation>
    <PMID>3595684</PMID>
  </reference>
  <reference>
    <citation>Chuang VP. Hepatic tumor angiography: a subject review. Radiology. 1983 Sep;148(3):633-9.</citation>
    <PMID>6878677</PMID>
  </reference>
  <reference>
    <citation>Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, Metreweli C, Johnson PJ, Li AK. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys. 1995 Nov 1;33(4):919-24.</citation>
    <PMID>7591903</PMID>
  </reference>
  <reference>
    <citation>YA PM, GUZMAN T, LOKEN MK, PERRY JF Jr. Isotope localization with tagged microspheres. Surgery. 1961 May;49:644-50.</citation>
    <PMID>13787028</PMID>
  </reference>
  <reference>
    <citation>LAFAVE JW, GROTENHUIS I, KIM YS, MACLEAN LD, PERRY JF Jr. Y90-tagged microspheres in adjuvant tumor therapy. Surgery. 1963 Jun;53:778-83.</citation>
    <PMID>13928002</PMID>
  </reference>
  <reference>
    <citation>GRADY ED, SALE WT, ROLLINS LC. Localization of radioactivity by intravascular injection of large radioactive particles. Ann Surg. 1963 Jan;157:97-114.</citation>
    <PMID>13949718</PMID>
  </reference>
  <reference>
    <citation>BLANCHARD RJ, GROTENHUIS I, LAFAVE JW, FRYE CW, PERRY JF Jr. TREATMENT OF EXPERIMENTAL TUMORS; UTILIZATION OF RADIOACTIVE MICROSPHERES. Arch Surg. 1964 Aug;89:406-10.</citation>
    <PMID>14160169</PMID>
  </reference>
  <reference>
    <citation>Stribley KV, Gray BN, Chmiel RL, Heggie JC, Bennett RC. Internal radiotherapy for hepatic metastases I: The homogeneity of hepatic arterial blood flow. J Surg Res. 1983 Jan;34(1):17-24.</citation>
    <PMID>6823100</PMID>
  </reference>
  <reference>
    <citation>Mauderly JL, Pickrell JA, Hobbs CH, Benjamin SA, Hahn FF, Jones RK, Barnes JE. The effects of inhaled 90Y fused clay aerosol on pulmonary function and related parameters of the beagle dog. Radiat Res. 1973 Oct;56(1):83-96.</citation>
    <PMID>4743733</PMID>
  </reference>
  <reference>
    <citation>Hill JW, Whitehead WS, Cameron JD, Hedgecock GA. Glass fibres: absence of pulmonary hazard in production workers. Br J Ind Med. 1973 Apr;30(2):174-9.</citation>
    <PMID>4703089</PMID>
  </reference>
  <reference>
    <citation>Russell JL Jr, Carden JL, Herron HL. Dosimetry calculations for yttrium-90 used in the treatment of liver cancer. Endocurietherapy/Hyperthermia Oncology. 1988; 4:171-186.</citation>
  </reference>
  <reference>
    <citation>Boos G, Thirwell M, Blanchard R, et al. Phase I-II study of hepatic arterial infusion of yttrium-90 (Y-90) glass microspheres in cancer of the liver. Proc Am Soc Clin Oncol. 1989, 8:103.</citation>
  </reference>
  <reference>
    <citation>Patt YZ, Charnsangavej C, Boddie A, et al. Treatment of hepatocellular carcinoma with hepatic arterial floxuridine, doxorubicin, and mitomycin C (FUDRM) with or without hepatic arterial embolization: factors associated with longer arterial survival. Reg Cancer Treat. 1989; 2:98.</citation>
  </reference>
  <reference>
    <citation>Douglass C. Prolongation of survival with periodic percutaneous multi-drug arterial infusions in patients with primary and metastatic gastrointestinal carcinoma to liver, abstracted. Proc Am Soc Clin Oncol. 1980; 21:416</citation>
  </reference>
  <reference>
    <citation>Stuart K. Invited commentary on preoperative lipiodol for unresectable HCC. World J Surg 1996; 20:331</citation>
  </reference>
  <reference>
    <citation>Harbert JC, Ziessman HA. Therapy with intra-arterial microspheres. Nuclear Medicine Annual 1987, edited by Freeman L.M., Weissman H.S. Raven Press, New York.</citation>
  </reference>
  <reference>
    <citation>Dancey JE, Shepherd FA, Paul K, Sniderman KW, Houle S, Gabrys J, Hendler AL, Goin JE. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000 Oct;41(10):1673-81.</citation>
    <PMID>11037997</PMID>
  </reference>
  <reference>
    <citation>Prinzmetal MB, Simkin B, Bergman HC, Kruger, HE. Studies on coronary circulation. American Heart Jornal. 1947; 33:420.</citation>
  </reference>
  <reference>
    <citation>PRINZMETAL M, ORNITZ EM Jr, et al. Arterio-venous anastomoses in liver, spleen, and lungs. Am J Physiol. 1948 Jan 1;152(1):48-52.</citation>
    <PMID>18903426</PMID>
  </reference>
  <reference>
    <citation>Gross P. The effects of fibrous glass dust on the lungs of animals. In: Occupational exposure to fibrous glass of a symposium presented to the Center of Adult Education; 1976; University of Maryland, College Park, MD. 169-178.</citation>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

